UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 15, 2004
HemaCare Corporation
(Exact name of registrant as specified in its charter)
California 000-15223 95-3280412
(State or other (Commission (IRS Employer
jurisdiction File Number) Identification No.)
of incorporation)
21101 Oxnard Street,Woodland Hills, CA 91367
(Address of principal executive offices) (Zip Code)
(Registrant's telephone number, including area code): 818-226-1968
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
2
Item 2.02 Results of Operations and Financial Condition
---------------------------------------------------------
On November 15, 2004, HemaCare Corporation issued a press
release announcing financial results for the third quarter of
2004. A copy is attached as Exhbit 99.1 to this report and
is incorporated herein by reference.
Attached to the Release is a table of condensed consolidated
financial data. This table inadvertantly indicated that
Other Income for the nine month period ended September 30,
2004 was zero instead of the correct amount of $167,000.
All of the other numbers presented in the table of condensed
consolidated financial data are correct as originally published
and are unaffected by this correction. The information corrected
in this Current Report on Form 8-K was accurately reported in
the Company's report on Form 10-Q filed with the SEC on
September 15, 2004.
On November 15, 2004, HemaCare Corporation held an investor
conference call discussing the financial results for the
third quarter of 2004. A transcript, of the presentations
given by Ms. Judi Irving, CEO, and Robert S. Chilton, CFO, is
attached to this report as Exhibit 99.2 and is incorporated
herein by reference.
The information in this Current Report on Form 8-K, including the
exhibits, will not be treated as "filed" for the purposes of
Section 18 of the Securities and Exchange Act of 1934 (the
"Exchange Act") or otherwise subject to the liabilities of
that section. This information will not be incorporated by
reference into a filing under the Securities Act of 1933, or into
another filing under the Exchange Act, unless that filing
expressly refers to specific information in this report.
Item 9.01 Financial Statements and Exhibits
-------------------------------------------
(c) Exhibits
Exhibit
Number Description
-------- ---------------------------------------------
99.1 Press Release dated November 15, 2004.
99.2 Transcript of the presentations given by
Judi Irving, CEO, and Robert S. Chilton,
CFO, at a conference call conducted by
HemaCare Corporation on November 15, 2004
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
HEMACARE CORPORATION
(Registrant)
Date: November 15, 2004 By: /s/ Robert S. Chilton
_______________________________
Robert S. Chilton,
Chief Financial Officer
2
3
EXHIBIT INDEX
Exhibit
Number Description
-------- ---------------------------------------------
99.1 Press Release dated November 15, 2004.
99.2 Transcript of the presentations given by
Judi Irving, CEO, and Robert S. Chilton,
CFO, at a conference call conducted by
HemaCare Corporation on November 15, 2004
3